Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

To assess the level of activity and toxicity of gefitinib (ZD1839, Iressa™) in a population of patients with locally recurrent and/or metastatic head and neck cancer. Patients were recruited into an expanded access programme through the multidisciplinary head and neck clinics at the Royal Marsden an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirby, A M, A'hern, R P, D'ambrosio, C, Tanay, M, Syrigos, K N, Rogers, S J, Box, C, Eccles, S A, Nutting, C M, Harrington, K J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361202/
https://www.ncbi.nlm.nih.gov/pubmed/16495923
http://dx.doi.org/10.1038/sj.bjc.6602999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361202/
https://www.ncbi.nlm.nih.gov/pubmed/16495923
http://dx.doi.org/10.1038/sj.bjc.6602999

Ejemplares similares